Skip to main content
Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. — Investor Relations & Filings

Ticker · 300759 ISIN · CNE100003JW4 LEI · 300300JYXHGVS5SNGG54 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2025-04-03 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300759

About Pharmaron Beijing Co., Ltd.

https://www.pharmaron.cn

Pharmaron Beijing Co., Ltd. is a premier R&D service provider for the life sciences industry, offering a comprehensive, fully integrated platform for drug discovery, development, and manufacturing. The company supports global pharmaceutical and biotechnology partners through a wide range of services, including laboratory chemistry, biology, DMPK, pharmacology, and safety assessment. Its capabilities extend to clinical development services and commercial-scale manufacturing for small molecules, biologics, and cell and gene therapies. By leveraging advanced technology and a global network of facilities, the company facilitates the transition of drug candidates from initial concept to market approval, optimizing the efficiency and success of the drug development lifecycle.

Recent filings

Filing Released Lang Actions
H股公告
Share Issue/Capital Change Classification · 95% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipts issuer under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, treasury shares, and other share-related information for the month ending March 31, 2025. The document is structured as a regulatory compliance report submitted to the Hong Kong Stock Exchange, focusing on share capital and shareholding changes. It does not contain financial statements, earnings data, management discussion, or audit information. It is not an announcement of a report publication but a substantive monthly report on share capital changes. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2025-04-03 Chinese
关于2024年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2024 profit distribution plan of the company Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd. It details the cash dividend distribution, share repurchase, and related financial figures. It references the 2024 audited net profit and the board and supervisory committee meeting resolutions approving the plan. The document is relatively short (3048 characters) and primarily serves to inform shareholders about the dividend plan and related financial data, rather than presenting a full financial report or audit report. It also mentions the existence of the 2024 audit report as a reference document but does not contain the audit report itself. This type of document fits the category of Notice of Dividend Amount (DIV), as it announces dividend amounts, payment details, and related shareholder information.
2025-03-26 Chinese
关于拟续聘2025年度境内财务及内控审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the company's domestic financial and internal control audit institution for the year 2025. It details the auditing firm information, their qualifications, independence, audit fees, and the approval process by the board, audit committee, and supervisory board. The document does not contain actual audit reports or financial statements but is a formal announcement about the selection and continuation of the audit firm. The document length is 3152 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. However, given the document is primarily an announcement of the audit firm reappointment and related information, it aligns best with the Audit Report / Information (AR) category rather than a Regulatory Filing (RNS) or Report Publication Announcement (RPA). FY 2025
2025-03-26 Chinese
关于2025年度对外担保额度预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 康龙化成（北京）新药技术股份有限公司 regarding the expected external guarantee limit for the year 2025. It includes extensive financial data of subsidiaries, descriptions of guarantee arrangements, board meeting approvals, and compliance with regulatory requirements. The document is not a full financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about the company's external guarantee limits and related board decisions, which fits best under the category of Regulatory Filings (RNS). The document length (8472 characters) and content confirm it is a substantive regulatory announcement rather than a brief notice or a full financial report.
2025-03-26 Chinese
《公司章程》（2025年3月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 康龙化成（北京）新药技术股份有限公司, dated March 2025. It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, share transfer, and other corporate governance matters. It references relevant laws and listing rules, and includes detailed provisions on shareholder meetings, board responsibilities, and financial accounting systems. This document is a governance document that sets out the internal rules and structure of the company rather than a financial report or announcement. It is not an Annual Report, Interim Report, or any financial statement. It is not a notice or announcement of voting results or dividends. It is not a transcript or presentation. It is a detailed governance document, matching the description of Governance Information (CGR). The document length is substantial and contains the full text of the company's articles, not just an announcement or summary, so it is not RPA or RNS. Therefore, the correct classification is Governance Information (CGR).
2025-03-26 Chinese
《股东提名个别人士为本公司董事之程序》（2025年3月）
Governance Information Classification · 95% confidence The document details the procedures for shareholders to nominate individuals as directors of the company, referencing company bylaws and Hong Kong Stock Exchange listing rules. It focuses on governance processes related to board nominations rather than financial results, audit, or other report types. There is no indication of an actual meeting presentation, voting results, or management changes announcement. The content aligns with governance information about internal rules and board structure.
2025-03-26 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.